A Review of Therapeutic Antibodies in Breast Cancer


  • Maryam Eini
  • Nahid Zainodini
  • Hamed Montazeri
  • Parastoo Mirzabeigi
  • Parastoo Tarighi Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran




Since the first production of monoclonal antibodies about 35 years ago, researchers have found them useful in the treatment and diagnosis of various diseases such as cancer. By developing different types of monoclonal antibodies such as humanized, drug conjugated, or bispecific ones, researchers, have achieved remarkable success in treating several complicated and challenging diseases, targeting specific antigens or receptors makes monoclonal antibodies the right choice to inhibit signaling pathways like programmed death-ligand 1 (PD-L1) or programmed death1 (PD-1) and changing cell behavior. As one of the most common types of malignancies among women, breast cancer is one of the most critical conditions which different types of monoclonal antibodies were designed and produced to treat. Therefore, we reviewed these antibodies in breast cancer, their targets, and their efficacy and toxicity, with more focus on recent PD-L1or PD-1 inhibitor antibodies in breast cancer and beyond.


Download data is not yet available.




How to Cite

Eini, M., Zainodini, N., Montazeri, H., Mirzabeigi, P., & Tarighi, P. (2021). A Review of Therapeutic Antibodies in Breast Cancer. Journal of Pharmacy & Pharmaceutical Sciences, 24(3), 363–380. https://doi.org/10.18433/jpps31864



Review Articles